Breaking News, Collaborations & Alliances

Regulus, AstraZeneca To Develop microRNA

Regulus gets $28 million upfront for lead cardiovascular/metabolic program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Regulus Therapeutics has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets currently in preclinical development. These targets are focused on cardiovascular and metabolic diseases and oncology.    Regulus and AZ will collaborate on three microRNA targets, which include Regulus’ lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. Regulus will receive $28...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters